Myriad Genetics, Inc. announced that a study published in the Journal of Clinical Psychopharmacology found that the GeneSight® Psychotropic Test significantly reduced psychiatric hospitalizations in ...

The genetic-testing company Myriad Genetics' biggest up-and-coming product is a test that claims to match patients with depression to the best medications for them, based on their DNA. The test, ...

Dyslexia is a developmental disorder characterized by severe problems in the acquisition of reading and writing skills. It has a strong neurobiological basis. Genetic influence is estimated at 50–70%.

Direct to consumer genetic health tests are popular but is taking one a good idea? We brought in genetics counselor Karin Dent to explain the realities of at-home genetics testing and why it’s ...

For diseases like depression, finding medications that work well for patients can be a long, arduous journey. Genetic tests now claim to speed it along by giving doctors more information about how ...

Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and ...